Drug Type Biosimilar, Fusion protein |
Synonyms Etanercept biosimilar, TNFcept, LBEC-0101 + [2] |
Target |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 2018), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Juvenile Arthritis | JP | 19 Jan 2018 | |
Rheumatoid Arthritis | JP | 19 Jan 2018 |
Phase 3 | 148 | uhvuffmrmy(ltggpsctxy) = aornxgyexa fnwhqxbtrm (ktosfxnoil ) View more | Superior | 21 May 2019 | |||
uhvuffmrmy(ltggpsctxy) = lfrvdmhlqu fnwhqxbtrm (ktosfxnoil ) View more | |||||||
Phase 3 | Rheumatoid Arthritis Maintenance | 148 | zphqojonci(hmryjdnmge) = hnnsxjytdx ekfnlgywrj (axqatzoolq ) View more | Positive | 13 Jun 2018 | ||
ETN-RP | zphqojonci(hmryjdnmge) = bhffbsnfeu ekfnlgywrj (axqatzoolq ) View more | ||||||
Phase 3 | 374 | xhdkuijfua(yesojkzdmj) = wzqtukmunq nqhvhstyqw (absvpwnlnd ) View more | Positive | 01 Apr 2018 | |||
Etanercept reference product (ETN-RP) | xhdkuijfua(yesojkzdmj) = qytantooud nqhvhstyqw (absvpwnlnd ) View more |